Leukotriene-associated inflammatory mediators

Leukotriene-associated inflammatory mediators refer to a group of lipid signaling molecules and the proteins involved in their biosynthesis and signaling that drive inflammatory responses (Haeggström & Funk, 2011). This pathway involves the conversion of arachidonic acid into leukotriene A4 (LTA4) by the enzyme arachidonate 5-lipoxygenase (5-LOX) and its helper protein FLAP (Peters-Golden & Henderson, 2007). LTA4 is further processed into leukotriene B4 (LTB4) or the cysteinyl leukotrienes (LTC4, LTD4, and LTE4), which are potent mediators of bronchoconstriction and vascular permeability (Kanaoka & Boyce, 2004). These molecules exert their biological effects by binding to specific G protein-coupled receptors, including CysLT1, CysLT2, BLT1, and BLT2 (Back et al., 2011). Pharmacological agents targeting this system, such as the 5-LOX inhibitor zileuton and CysLT1 receptor antagonists like montelukast, are standard treatments for asthma and allergic rhinitis (StatPearls, 2023). While effective, these drugs are associated with specific safety concerns, most notably the FDA boxed warning for neuropsychiatric events linked to montelukast (FDA, 2020). The pathway is also implicated in other inflammatory conditions, including COPD and cardiovascular disease, making it a broad area of therapeutic interest (Back et al., 2011). Monitoring efficacy often involves measuring urinary leukotriene levels or assessing clinical improvements in lung function (StatPearls, 2023).

Other names

LeukotrienesCysteinyl leukotrienes5-lipoxygenase pathway componentsLTsCysLTs

Antagonism of cysteinyl leukotriene receptors (CysLT1) and inhibition of the 5-lipoxygenase (5-LOX) enzyme.